On Friday, City and County officials joined with MedImmune in celebrating the official opening of their 2nd manufacturing facility in the City of Frederick.

The new 331,000 square foot facility began construction in 2006. Construction was completed in 201, and the process of FDA licensure began. The approval came in early 2011, and MedImmune is now licensed to begin production.

"The multimillion dollar expansion of MedImmune's manufacturing capacity here in Frederick is a terrific example of a match between workforce, access, land availability and proximity to the MedImmune Headquarters in Gaithersburg," stated Mayor McClement. "Congratulations to MedImmune and its leadership team led by their president, Peter Greenleaf, on a job well done."

The City of Frederick Department of Economic Development has been involved with the company officials on this expansion since it was first a concept nearly 10 years ago. Our planning, engineering and permits departments have worked hard to ensure that MedImmune could deliver this facility on-time," said the City's economic development director, Richard Griffin. "We are immensely proud of MedImmune, this facility and its employees. We hope to have a long future together."

MedImmue first established a presence in Frederick in 1996, opening a manufacturing facility to produce Synagis®, which is FDA-approved to prevent RSV in high-risk children. The new plant, which will expand MedImmune's production capacity for Synagis®  as well as future marketed monoclonal antibodies, is on the same site as the first facility. Currently, MedImmune employs nearly 250 at the Frederick facility.